Slovenia has temporarily suspended the use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccines after the death of a young woman, Reuters news agency reported on Wednesday, citing the STA national news agency.
STA reported that the patient had blood clots and bleeding in the brain at the same time and intensive care was not successful.
Health minister Janez Poklukar said he was not familiar with the details of the case.
"I can't make comments, but the conditions have been met for clarifying all the circumstances of what happened," he said.
The J&J Janssen COVID-19 vaccine is one of the several vaccines Slovenia is using in its vaccination programme.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV